Raymond James adds Profound Medical to “analyst current favorite”

Profound Medical Logo

Raymond James added Profound Medical (TSX:PRN; NASDAQ:PROF) as an “analyst current favorite,” maintaining a “strong buy” recommendation, after AstraZeneca and Merck received FDA approval for their PARP inhibitor drug, olaparib, for treatment of homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer (mCRPC). 

“The read-through from olaparib’s FDA nod notwithstanding, “we note that Profound’s stock price has, at points over the last few days, slipped below $16 (Canadian). Based on our valuation of Profound, we regard this price level a no-brainerentry point,” writes analyst Rahul Sarugaser. Shares of Profound closed at $15.69 on May 21.

Mr. Sarugaser said that olaparib represents one of the first molecularly-targeted treatments in prostate cancer. 

However, “we do not view olaparib as a therapy that would cannibalize Profound’s TULSA-PRO sales,” he added. “On the contrary, we see the two treatments as complementary, providing a one-two punch: for men with non-metastatic BRCA/ATM-mutant prostate cancer, physicians could first ablate the prostate using TULSA-PRO, and, should the patient subsequently develop metastatic disease, olaparib treatment will be waiting in the wings.” 

For non-metastatic and/or non-BRCA/ATM-mutant prostate cancer, the point is moot: “TULSA-PRO remains our treatment of choice,” he added. 

Profound’s TULSA-PRO medical device is a proprietary platform that offers an efficacious, incision-free alternative treatment option for prostate cancer and benign prostatic hyperplasia, a non-cancerous enlargement of the prostate gland.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.